Oral oseltamivir in human experimental influenza B infection.

@article{Hayden2000OralOI,
  title={Oral oseltamivir in human experimental influenza B infection.},
  author={Frederick G. Hayden and Lance Jennings and R. M. Reecy Robson and Gilbert M. Schiff and Helen Jackson and Binay Rana and Grant B. McClelland and David Ipe and Noel K. Roberts and Penelope Ward},
  journal={Antiviral therapy},
  year={2000},
  volume={5 3},
  pages={205-13}
}
Oseltamivir is the prodrug of Ro64-0802 (GS4071), a potent and selective inhibitor of influenza A and B virus neuraminidases. Three randomized, double-blind, placebo-controlled, parallel-group studies evaluated oral oseltamivir for early treatment (75 or 150 mg twice daily for 5 days) or prevention (75 mg once or twice daily for 7 days) of experimental influenza B virus infection in healthy susceptible adults. Treatment study A (n=60) demonstrated similar trends to treatment study B (n=117), in… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

Population pharmacokinetics of oseltamivir: pediatrics through geriatrics.

Antimicrobial agents and chemotherapy • 2013
View 5 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…